HK$12.55
2.03%
Hong Kong, Sep 18, 03:46 pm HKT. Closed.
ISIN
KYG1996C1006
Symbol
2171

Carsgen Therapeutics Holding Target price 2026 - Analyst rating & recommendation

Carsgen Therapeutics Holding Classifications & Recommendation

Buy
78%
Hold
11%
Sell
11%

Carsgen Therapeutics Holding Price Target

Target Price HK$18.68
Price HK$12.75
Potential
Number of Estimates 4
4 Analysts have issued a price target Carsgen Therapeutics Holding 2027 . The average Carsgen Therapeutics Holding target price is HK$18.68. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 7 Analysts recommend Carsgen Therapeutics Holding to buy, 1 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Carsgen Therapeutics Holding stock has an average upside potential 2027 of . Most analysts recommend the Carsgen Therapeutics Holding stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Million HK$ 147.15 353.81
218.71% 140.44%
EBITDA Margin -157.88% -54.36%
87.20% 65.57%
Net Margin -77.87% -44.70%
96.15% 42.60%

5 Analysts have issued a sales forecast Carsgen Therapeutics Holding 2026 . The average Carsgen Therapeutics Holding sales estimate is

HK$354m
unlock
. This is
121.16% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HK$429m 168.07%
unlock
, the lowest is
HK$305m 90.81%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 HK$147m 218.71%
2026
HK$354m 140.44%
unlock
2027
HK$787m 122.46%
unlock
2028
HK$1.7b 115.12%
unlock

5 Analysts have issued an Carsgen Therapeutics Holding EBITDA forecast 2026. The average Carsgen Therapeutics Holding EBITDA estimate is

HK$-192m
unlock
. This is
15.86% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HK$-120m 47.63%
unlock
, the lowest is
HK$-269m 17.47%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 HK$-232m 59.21%
2026
HK$-192m 17.21%
unlock
2027
HK$-49.3m 74.39%
unlock
2028
HK$451m 1,016.47%
unlock

EBITDA Margin

2025 -157.88% 87.20%
2026
-54.36% 65.57%
unlock
2027
-6.26% 88.48%
unlock
2028
26.66% 525.88%
unlock

5 Carsgen Therapeutics Holding Analysts have issued a net profit forecast 2026. The average Carsgen Therapeutics Holding net profit estimate is

HK$-158m
unlock
. This is
51.45% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HK$-49.7m 52.39%
unlock
, the lowest is
HK$-287m 174.46%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 HK$-115m 87.74%
2026
HK$-158m 38.02%
unlock
2027
HK$-66.1m 58.23%
unlock
2028
HK$382m 678.82%
unlock

Net Margin

2025 -77.87% 96.15%
2026
-44.70% 42.60%
unlock
2027
-8.39% 81.23%
unlock
2028
22.58% 369.13%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share HK$ -0.21 -0.27
87.57% 28.57%
P/E negative
EV/Sales 16.52

5 Analysts have issued a Carsgen Therapeutics Holding forecast for earnings per share. The average Carsgen Therapeutics Holding EPS is

HK$-0.27
unlock
. This is
42.11% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
HK$-0.08 57.89%
unlock
, the lowest is
HK$-0.48 152.63%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 HK$-0.21 87.57%
2026
HK$-0.27 28.57%
unlock
2027
HK$-0.11 59.26%
unlock
2028
HK$0.64 681.82%
unlock

P/E ratio

Current -67.11 259.03%
2026
-47.94 28.56%
unlock
2027
-114.78 139.42%
unlock
2028
19.83 117.28%
unlock

Based on analysts' sales estimates for 2026, the Carsgen Therapeutics Holding stock is valued at an EV/Sales of

16.52
unlock
and an P/S ratio of
20.66
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 36.53
2026
16.52 54.78%
unlock
2027
7.42 55.05%
unlock
2028
3.45 53.52%
unlock

P/S ratio

Current
2026
20.66 54.78%
unlock
2027
9.29 55.05%
unlock
2028
4.32 53.52%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today